Neoadjuvant docetaxel in high-risk prostate cancer

Neoadjuvant docetaxel in patients with high-risk prostate cancer - NAC in HRPC

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs021180009

Enrollment

150

Registered

2019-03-25

Start date

2015-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer prostate cancer, high-risk

Interventions

Neoadjuvant treatment with androgen deprivation therapy, docetaxel and estramustine phosphate followed by radical prostatectomuy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: pathologically diagnosed high-risk prostate cancer who have a plan to receive surgical treatment

Exclusion criteria

Exclusion criteria: .Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
surgical CR rate	—

Secondary

Measure	Time frame
biochemical recurrence, cancer specific survival, overall survival, adverse event	—

Contacts

Public ContactShintaro Narita

Akita University School of Medicine

naritashintaro@gmail.com+81-18-884-6156

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026